To investigate at which step JAM-C is involved in EPC recruitment to develop tumor vasculature, we used a specific monoclonal antibody against JAM-C (H33) that was previously proven to inhibit angiogenesis and tumor growth [30]. The gene discussed is JAM3; the disease is neoplasm.